The MHRA has launched a Safety Features e-mail newsletter dedicated to developments in implementing the EU Falsified Medicines Directive (FMD) in the UK.
The first issue covers work that has been undertaken since the publication of the EU Delegated Regulation (2016/161) which sets 9th February 2019 as the starting date for FMD authentication.
Those wanting to receive the newsletter can register with the MHRA by sending their name, organisation and job title (if applicable) to FMD.email@example.com. General enquiries about the implementation of safety features (unique identifiers and anti-tamper devices on medicine packs) can be directed to the same mailbox. A response is promised within five working days.